Brief: Precigen Announces Further Advancement Of UltraCAR-T Platform
29/03/2023 13:21
March 29 (Reuters) - Precigen Inc PGEN.O :
* PRECIGEN ANNOUNCES FURTHER ADVANCEMENT OF ULTRACAR-T®
PLATFORM
WITH FIRST PATIENT DOSED IN PHASE 1/1B DOSE ESCALATION/DOSE
EXPANSION STUDY OF PRGN-3007 IN ADVANCED ROR1+ HEMATOLOGICAL AND
SOLID TUMORS
Source text for Eikon: ID:nPn4d36rRa
Further company coverage: PGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precigen
See all newsBrief: Precigen Receives FDA Platform Technology Designation For Adenoverse Platform
Precigen, Inc. reports results for the quarter ended June 30 - Earnings Summary
Precigen posts quarterly profit as PAPZIMEOS sales surge
Precigen Inc expected to post a loss of 1 cent a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Advanced Energy, Bel Fuse, Cerebras